The FTC sued Amare Global Holdings and three executives on June 2, 2026, alleging the multi-level marketing company deceptively promoted dietary supplements — including products aimed at children — as treatments for depression, anxiety, and ADHD, and made deceptive income promises to recruits, per the FTC, 2026. The complaint was filed in federal court in the Central District of California.
This site publishes information, not medical or legal advice. A complaint contains allegations, not findings; the case must be proven, and the defendants can contest it in court. Nothing here should be read as a final judgment about the company or any person. If your child struggles with mood or attention, the right first stop is a pediatric clinician, not a supplement.
What does the FTC allege Amare claimed?
The agency's complaint names products including Happy Juice, Kids Mood+, and Kids Happy Juice, and alleges claims that the supplements could treat depression, anxiety, and ADHD, and could affect cortisol, serotonin, dopamine, and GABA — without competent and reliable scientific evidence, per the FTC, 2026. The FTC also alleges deceptive earnings claims, such as recruits being told they could earn "$500 a month" or replace their income regardless of experience or social-media following.
Two of the named defendants — former chief science officer Shawn Talbott and founding brand partner Patrick Hintze — were allegedly already subject to prior FTC orders barring unsubstantiated claims, per the FTC, 2026. The products were promoted by "brand partners" on Instagram, TikTok, YouTube, and Facebook, according to the complaint.
Related stories: FTC Finalizes $4M Order Against Kids' Height Supplements · FDA Warning Letter Hits Bee Supplement Maker CC Pollen.
Why does this case matter for the wellness industry?
Because it pairs two of the FTC's recurring targets: disease claims for supplements and income claims in multi-level marketing. Bureau of Consumer Protection Director Christopher Mufarrige said the claims were "not only deceptive but dangerous," noting parents sought help for children with serious conditions, per the FTC, 2026. For any wellness company selling through social media, the case signals that disease-treatment language from independent promoters can land on the company itself.
What this changes for readers
Treat any supplement pitched as a fix for depression, anxiety, or ADHD — for you or your child — as a red flag, whatever the platform. Under US law, supplements cannot legally be marketed as treating diseases, per the FTC, 2026. If someone selling a product promises mood cures plus an income opportunity, you are looking at both problems the FTC alleges in this case at once.
The bottom line
Per the FTC, June 2, 2026, the agency alleges Amare Global marketed mood and kids' supplements as disease treatments and dangled unrealistic earnings to recruits. The allegations are contested and unresolved. For readers, the standing rule holds: supplements are not depression or ADHD treatments — that conversation belongs with a clinician.